First-in-Human Trial of VBC106 in Participants With Advanced Solid Tumors
Part of paid clinical trials in Houston, Texas.
- Sponsor
- VelaVigo Bio Inc
- Study ID
- NCT07686068
- Phase
- PHASE1/PHASE2
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Participants With Advanced Solid Tumor Malignancies
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- VBC106 — DRUGVBC106
Study Details
This is a multicenter, open-label, multiple-dose, FIH Phase 1/2a trial. The Phase 1 portion adopts BOIN design to identify the MTD and/or RP2D with potential backfill cohorts. The Phase 2a portion consists of dose optimization followed by cohort expansion to confirm safety and tolerability and to further evaluate the efficacy of the selected RP2D in selected solid tumor malignancies for VBC106.
Key Dates
- Start date
- Aug 18, 2026
- Status verified
- Jun 2026
- Primary completion
- Dec 1, 2028
- Completion
- Dec 1, 2028
Study Design
- Enrollment
- 260 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Phase 1 (Dose Escalation and Backfill)，Phase 2（Dose optimization and Cohort Expansion）
Primary Outcome Measure
Incidence of dose-limiting toxicities (DLT) as defined in the protocol [ Time Frame: (DLT)From time of first dose of VBC106 to end of DLT period (approximately 21 days) ]
Central Contacts
- Feng Guo17368707951
Locations (3)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| NEXT Oncology Houston | Houston | Texas | 77054 | |
| START Mountain Region, LLC. | West Valley City | Utah | 84119 | |
| NEXT Oncology Virginia | Fairfax | Virginia | 22031 |
Find similar trials in Houston, TX
Related Studies
- First-in-Human Trial of VBC101 in Participants With Advanced Solid Tumor MalignanciesPHASE1/PHASE2 · Recruiting · VelaVigo Bio Inc · Grand Rapids, Michigan